| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 27 Feb 2025 | 13 Feb 2025 |
| Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/02/2025 inter alia to consider and approve the Audited Finacial Statements (Standalone & Consolidated) for the Quarter and Financial Year ended 31st December 2024 and Recommendation of Final Dividend if any. We enclose a copy of the approved Standalone and Consolidated Financial Results for the Quarter and Financial Year Ended 31St December 2024 and recommended Final dividend of Rs. 117/- per equity share of face value of Rs. 10 each. (As Per BSE Announcement Dated 27.02.2025) | ||
| Board Meeting | 11 Feb 2025 | 11 Feb 2025 |
| Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for appointment of Company Secretary and Compliance Officer | ||
| Board Meeting | 7 Nov 2024 | 17 Oct 2024 |
| Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2024 inter alia to consider and approve the Unaudited Financial Statements (Standalone & Consolidated) for the quarter and nine months ended 30th September 2024. We refer to our letter dated 17th October 2024 informing you of our Board Meeting that was scheduled today. In this regard, we wish to inform you that the Board of Directors at its meeting held today i.e., Thursday, 7th November 2024, inter-alia considered and approved Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended 30th September 2024. A copy of the Press Release issued in this regard is enclosed. (As Per BSE Announcement dated on 07.11.2024) | ||
| Board Meeting | 26 Jul 2024 | 8 Jul 2024 |
| Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2024 inter alia to consider and approve the Unaudited Financial Statements (Standalone & Consolidated) for the quarter and half year ended 30th June 2024. We refer to our letter dated 8th July 2024 informing you of our Board Meeting that was scheduled today. In this regard, we wish to inform you that the Board of Directors at its meeting held today i.e., Friday, 26th July 2024, inter-alia considered and approved the Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended 30th June 2024. A copy of the Press Release issued in this regard is enclosed. Enclosed (As per BSE Announcement Dated on 26/07/2024) | ||
| Board Meeting | 13 May 2024 | 26 Apr 2024 |
| Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2024 inter alia to consider and approve the Unaudited Financial Statements (Standalone & Consolidated) for the Quarter ended 31st March 2024. We wish to inform you that the Board of Directors at its meeting held today i.e. Monday, 13th May 2024, based on the recommendation of the Nomination and Remuneration Committee, have approved the appointment of Mr. Eric Mansion as a Non-Executive Director of the Company with effect from 3rd June 2024, subject to the approval of the Members of the Company through Postal Ballot. Unaudited standalone and consolidated financial results for the quarter ended 31st March 2024. (As Per BSE Announcement Dated on 13/05/2024) | ||
The board has proposed a final dividend of ₹117 per equity share (face value of ₹10), subject to shareholders approval at the next Annual General Meeting.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
